What question did this study set out to answer?

To overview emerging pharmacological strategies for treating and preventing proliferative vitreoretinopathy (PVR).

Drug strategies for the treatment and prevention of proliferative vitreoretinopathy: an overview of innovative treatment concepts

View Full Paper

Ask AI

Bookmark

Authors

This review presents innovative pharmacological strategies targeting proliferative vitreoretinopathy, suggesting essential future trials.

To overview emerging pharmacological strategies for treating and preventing proliferative vitreoretinopathy (PVR).
Review of experimental and clinical evidence on pharmacological agents for PVR.
Examination of mechanisms like epithelial-mesenchymal transition and profibrotic cytokine signaling.
Evaluation of clinically tested and novel compounds for their therapeutic potential.
Several agents exhibit anti-proliferative and anti-inflammatory effects in vitro and in vivo.
Methotrexate and infliximab show promise as treatment options.
No pharmacological agent has received regulatory approval for PVR.

Luyken et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark